We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
Read MoreHide Full Article
Key Takeaways
Cytokinetics launched Myqorzo in the US and Germany after FDA and European Commission approvals.
CYTK seeks to expand Myqorzo's label as the FDA reviews its MAPLE-HCM supplemental application.
CYTK reported positive phase III ACACIA-HCM results supporting aficamten in non-obstructive HCM.
Cytokinetics, Incorporated (CYTK - Free Report) has entered a pivotal phase following the FDA approval of its first drug, Myqorzo (aficamten), for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
The approval marks the company’s transition into a commercial-stage biotech.
Myqorzo is an allosteric and reversible inhibitor of cardiac myosin motor activity. It is approved in the United States and China for the treatment of adults with symptomatic oHCM.
The commercial outlook for Myqorzo appears promising. The company initiated the U.S. commercial rollout in January 2026. Early launch metrics indicate strong physician engagement and patient uptake, with over 275 unique healthcare providers prescribing the drug and approximately 680 patients being prescribed Myqorzo by the end of the first quarter.
More than 70% of patients on therapy transitioned to paid prescriptions.
International expansion provides an additional growth lever. The European Commission approval in February 2026 further expands Myqorzo's addressable market.
Cytokinetics recently achieved an important commercial milestone with the first European launch of Myqorzo in Germany, marking the drug's entry into the EU market.
CYTK is also working on a label expansion of Myqorzo. The FDA accepted its supplemental new drug application for MAPLE-HCM, a phase III study of aficamten as monotherapy compared with metoprolol as monotherapy in patients with oHCM. The regulatory body assigned a target action date of Nov. 14, 2026.
Meanwhile, aficamten continues to be evaluated across additional patient populations, supporting potential lifecycle expansion opportunities. The drug was studied in the phase III ACACIA-HCM study in non-obstructive hypertrophic cardiomyopathy (nHCM).
The ACACIA-HCM study successfully met both co-primary endpoints, demonstrating statistically significant improvements from baseline through week 36 in both Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score and maximal exercise performance (peak VO2). Statistically significant improvements compared to placebo were also observed in key secondary endpoints.
The company’s tailored commercialization model, including dedicated cardiac account specialists and patient support programs, may further drive uptake.
Competition for CYTK’s Myqorzo
Myqorzo operates within an evolving treatment landscape for oHCM. Its primary branded competitor is Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb (BMY - Free Report) . In addition to this direct competition, Myqorzo faces established generic therapies, namely beta blockers and calcium channel blockers, which continue to serve as the first-line standard of care.
BMY obtained FDA approval for Camzyos in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III obstructive HCM to improve functional capacity and symptoms.
The drug continues to gain traction in the targeted market, supported by growing demand and increased adoption among eligible patients
The FDA accepted BMY’s supplemental new drug application seeking approval of Camzyos for the treatment of adolescentsaged 12 to under 18 years with symptomatic oHCM.
A potential competitor for Cytokinetics is Edgewise Therapeutics, Inc. (EWTX - Free Report) , whose cardiovascular program includes novel, oral, selective cardiac sarcomere modulators — EDG-7500 and EDG-15400.
Edgewise recently reported top-line results from the 12-week phase II Part D CIRRUS-HCM study of EDG-7500 in oHCM and nHCM. Consistent and clinically meaningful improvements were observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM.
EWTX expects to initiate a phase II study on EDG-15400 in participants with heart failure with preserved ejection fraction in the second half of 2026.
CYTK’s Price Movement, Valuation and Estimates
Cytokinetics’ shares have gained 35.5% year to date compared with the industry’s 6.3% growth.
Image Source: Zacks Investment Research
Going by the price/sales ratio, CYTK’s shares currently trade at 40.74X forward sales, higher than the industry’s average of 1.90X but lower than its mean of 49.04X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 loss per share has narrowed to $6.22 from $6.36 and that for 2027 has narrowed to $4.59 from $4.62 in the past 60 days.
View the Zacks #1 Rank List
Image: Bigstock
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
Key Takeaways
Cytokinetics, Incorporated (CYTK - Free Report) has entered a pivotal phase following the FDA approval of its first drug, Myqorzo (aficamten), for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
The approval marks the company’s transition into a commercial-stage biotech.
Myqorzo is an allosteric and reversible inhibitor of cardiac myosin motor activity. It is approved in the United States and China for the treatment of adults with symptomatic oHCM.
The commercial outlook for Myqorzo appears promising. The company initiated the U.S. commercial rollout in January 2026. Early launch metrics indicate strong physician engagement and patient uptake, with over 275 unique healthcare providers prescribing the drug and approximately 680 patients being prescribed Myqorzo by the end of the first quarter.
More than 70% of patients on therapy transitioned to paid prescriptions.
International expansion provides an additional growth lever. The European Commission approval in February 2026 further expands Myqorzo's addressable market.
Cytokinetics recently achieved an important commercial milestone with the first European launch of Myqorzo in Germany, marking the drug's entry into the EU market.
CYTK is also working on a label expansion of Myqorzo. The FDA accepted its supplemental new drug application for MAPLE-HCM, a phase III study of aficamten as monotherapy compared with metoprolol as monotherapy in patients with oHCM. The regulatory body assigned a target action date of Nov. 14, 2026.
Meanwhile, aficamten continues to be evaluated across additional patient populations, supporting potential lifecycle expansion opportunities. The drug was studied in the phase III ACACIA-HCM study in non-obstructive hypertrophic cardiomyopathy (nHCM).
The ACACIA-HCM study successfully met both co-primary endpoints, demonstrating statistically significant improvements from baseline through week 36 in both Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score and maximal exercise performance (peak VO2). Statistically significant improvements compared to placebo were also observed in key secondary endpoints.
The company’s tailored commercialization model, including dedicated cardiac account specialists and patient support programs, may further drive uptake.
Competition for CYTK’s Myqorzo
Myqorzo operates within an evolving treatment landscape for oHCM. Its primary branded competitor is Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb (BMY - Free Report) . In addition to this direct competition, Myqorzo faces established generic therapies, namely beta blockers and calcium channel blockers, which continue to serve as the first-line standard of care.
BMY obtained FDA approval for Camzyos in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III obstructive HCM to improve functional capacity and symptoms.
The drug continues to gain traction in the targeted market, supported by growing demand and increased adoption among eligible patients
The FDA accepted BMY’s supplemental new drug application seeking approval of Camzyos for the treatment of adolescentsaged 12 to under 18 years with symptomatic oHCM.
A potential competitor for Cytokinetics is Edgewise Therapeutics, Inc. (EWTX - Free Report) , whose cardiovascular program includes novel, oral, selective cardiac sarcomere modulators — EDG-7500 and EDG-15400.
Edgewise recently reported top-line results from the 12-week phase II Part D CIRRUS-HCM study of EDG-7500 in oHCM and nHCM. Consistent and clinically meaningful improvements were observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM.
EWTX expects to initiate a phase II study on EDG-15400 in participants with heart failure with preserved ejection fraction in the second half of 2026.
CYTK’s Price Movement, Valuation and Estimates
Cytokinetics’ shares have gained 35.5% year to date compared with the industry’s 6.3% growth.
Image Source: Zacks Investment Research
Going by the price/sales ratio, CYTK’s shares currently trade at 40.74X forward sales, higher than the industry’s average of 1.90X but lower than its mean of 49.04X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 loss per share has narrowed to $6.22 from $6.36 and that for 2027 has narrowed to $4.59 from $4.62 in the past 60 days.
Image Source: Zacks Investment Research
CYTK currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.